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TWO & A HALF PARENTS: THREE-PARENT IVF AND MEDICAL 
MALPRACTICE IN THE UNITED STATES 
Jay M. Fulk* 
Fertility medicine is seeing a rapid advancement with the emergence 
of a new procedure called three-parent in vitro fertilization (IVF). This novel 
procedure provides an opportunity for women who have defective 
mitochondria to bear their own healthy genetic children. As women 
encounter fertility issues, they will often turn to regular IVF by receiving an 
egg from a donor—ultimately resulting in a child with no genetic relation to 
the mother. 
Women with defective mitochondria will likely pass down a 
mitochondrial disease to their children, therefore, bearing a child without the 
assistance from a donor does not present a viable option. Mitochondrial 
disease can be quite severe and traumatic, usually affecting the central 
nervous system. It can contribute to many serious illnesses such as 
Parkinson’s, Alzheimer’s, and cancer. Currently, there are no treatment 
options available for people with mitochondrial disease. Regular IVF 
requires an egg from a donor to replace the mothers egg, therefore, the 
mother is not genetically related to the child she bears, as the egg donor is 
the genetic mother. Three-parent IVF is a breakthrough fertility treatment 
procedure that allows women with defective mitochondria to bear a healthy 
child by receiving healthy mitochondria from a donor. This procedure 
enables women to retain a genetic bond to their child. Since a donor’s healthy 
mitochondria is transferred to the mother’s egg, the child will technically 
have three genetic parents (two mothers and a father). 
                                                     
* 2017–2018 Associate Editor, 2018–2019 Executive Managing Editor, Concordia Law 
Review. J.D. Candidate 2019, Concordia University School of Law; B.A. University of 
Alaska Fairbanks. The author first wishes to thank his wife, Paula, for her unwavering 
support. Additional thanks to Professor Katharine Van Tassel for her invaluable mentorship 
and assistance with research, as well as to Professor Victoria Haneman for her inspiration of 
the topic and her instruction on academic legal writing. Lastly, thanks to the editors of the 
Concordia Law Review for their feedback and editorial support, along with their dedication 
and professionalism throughout the process. Any errors are mine.  
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Three-parent IVF is currently not allowed in the United States, but 
with responsible legislation, it could be legal in the near future. This 
Comment proposes that three-parent IVF is implemented as a clinical trial 
for the purposes of conducting research to assess for safety and effectiveness. 
Current safety regulations and guidelines, primarily those regarding human 
tissue donation and transplantation, are quite instructive when put in the 
three-parent IVF context. These regulations and guidelines are discussed in 
some detail. There are a couple of steps that need to be taken in order to 
successfully implement three-parent IVF in the United States. First, great 
strides need to be made to reform the broken medical malpractice system in 
the United States. Current medical malpractice standards, and the available 
remedies to fertility plaintiffs, are not adequate to accommodate such a 
procedure. This Comment proposes that we move away from the customary 
care standard, and towards an evidence-based standard of care, while 
adopting the reasonable patient standard of informed consent. These 
standards will help address the inefficiency problems that exist within the 
medical profession. Second, since medical malpractice lawsuits are too 
costly for most fertility plaintiffs to pursue, there needs to be a fertility court 
established within the United States Court of Federal Claims—following in 
the successful footsteps of vaccine court. A fertility court will give fertility 
plaintiffs a remedy when they are injured by a doctor’s negligence, when no 
such remedy would have otherwise been available. Also, the establishment of 
a fertility court will lower fertility doctor’s medical malpractice premiums by 
reducing their overall litigation liability—as fertility plaintiffs will primarily 
turn to fertility court to redress their injuries. 
The United Kingdom is leading the world into the future by being the 
first country to approve the three-parent IVF procedure. The time has come 
for the United States to take a serious look at three-parent IVF to help 
advance fertility medicine into a promising and hopeful future. 
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INTRODUCTION 
A revolution is currently underway. Three-parent in vitro 
fertilization1 (IVF) has burst onto the scene within reproductive health over 
                                                     
1 In Vitro Fertilization (IVF), MAYO CLINIC, https://www.mayoclinic.org/tests-procedures/in 
-vitro-fertilization/home/ovc-20206838 (last visited Feb. 24, 2018). Here is a brief and 
concise overview of IVF: 
In vitro fertilization (IVF) is a complex series of procedures used to treat 
fertility or genetic problems and assist with the conception of a child. 
During IVF, mature eggs are collected (retrieved) from [the] ovaries and 
fertilized by sperm in a lab. Then the fertilized egg (embryo) or eggs are 
implanted in [the] uterus. One cycle of IVF takes about two weeks. IVF is 
the most effective form of assisted reproductive technology. The 
procedure can be done using [the females] own eggs and [her] partner’s 
sperm. Or IVF may involve eggs, sperm or embryos from a known or 
anonymous donor. In some cases, a gestational carrier—a woman who has 
2018 TWO & A HALF PARENTS  203 
 
the last few years, which has sparked rigorous discussion and debate. In April 
2016, the world said hello to the first child conceived using three-parent IVF.2 
A couple from Jordan contacted Dr. John Zhang3 from New Hope Fertility 
Center in New York to assist them in conceiving a healthy child.4 The woman 
had “a condition called Leigh syndrome, a neurological condition that killed 
her two prior children.”5 Since the genes that carried this disease were 
transported within her mitochondrial DNA (mtDNA)—and since mothers 
pass down their mitochondria to their children—the only way for her to have 
a healthy child was a mitochondrial transplant.6 The baby boy was delivered 
in Mexico, since the mitochondrial transplant procedure is currently not 
allowed in the United States, and there are currently no regulations in place 
for Mexico.7 While the procedure is still new, Dr. Zhang continues to discuss 
his three-parent IVF activities—specifically about advertising the 
procedure—in the United States with the Food and Drug Administration  
                                                     
an embryo implanted in her uterus—might be used. [The] chances of 
having a healthy baby using IVF depend on many factors, such as [the 
females] age and the cause of infertility. In addition, IVF can be time-
consuming, expensive and invasive. If more than one embryo is implanted 
in [the] uterus, IVF can result in a pregnancy with more than one fetus 
(multiple pregnancy). 
Id.  
2 Andrew Joseph, World’s First Baby Born with Novel Three-Parent Embryo Technique, 
STAT (Sept. 27, 2016), https://www.statnews.com/2016/09/27/three-parent-baby-embryo/. 
3 John Zhang, John Zhang, MD, MsC, PhD, NEW HOPE FERTILITY CTR., https://www.new 
hopefertility.com/about-us/fertility-doctors/john-zhang/ (last visited Feb. 24, 2018). Dr. 
John Zhang is a fertility specialist and the “Founder/CEO of New Hope Fertility Center in 
New York City.” Id. He is considered to be a pioneer in the area of assisted reproductive 
technology (ART). Id. He earned his medical degree from Zhejiang University School of 
Medicine and his Ph.D. in In-Vitro-Fertilization (IVF). Id.  
Today, Dr. Zhang continues his research in non-embryonic stem cell 
research, long-term cryopreservation of oocytes, and oocyte (human egg 
cell) reconstruction by nuclear transfer. He is currently one of a handful of 
Reproductive endocrinologists in the United States to hold a Ph.D. in 
embryology while also being certified as a High Complexity Lab Director. 
Id. 
4 Joseph, supra note 2.  
5 Id.  
6 James D. McCully et al., Mitochondrial Transplantation: From Animal Models to Clinical 
Use in Humans, 34 MITOCHONDRION 127, 127 (2017) (“Mitochondrial transplantation is a 
novel therapeutic intervention to treat . . . disorders. The method for mitochondrial 
transplantation is simple and rapid and can be delivered to the end organ either by direct 
injection or vascular infusion.”).   
7 Joseph, supra note 2.   
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FDA).8 In January 2017, the first girl9 conceived using the three-parent IVF 
procedure was born in Kiev, Ukraine.10 
When confronted with fertility issues, women often turn to Assisted 
Reproductive Technology (ART).11 Fertility treatments can take many forms: 
ART is used to treat infertility. It includes fertility treatments 
that handle both a woman’s egg and a man’s sperm. It works 
by removing eggs from a woman’s body. The eggs are then 
mixed with sperm to make embryos. The embryos are then put 
back in the woman’s body. In vitro fertilization (IVF) is the 
most common and effective type of ART.12 
                                                     
8 Susan Scutti et al., FDA Warns ‘3-Parent’ Baby Fertility Doctor Over Marketing, CNN 
(Aug. 7, 2017, 10:49 AM), http://www.cnn.com/2017/08/07/health/fda-3-parent-fertility-
zhang/index.html. Since Dr. Zhang performed the three-parent IVF procedure in Mexico, he 
has been advertising three-parent IVF as a service offered by New Hope Fertility Center. Id. 
The FDA sent Dr. Zhang a letter, warning him that marketing the technique is not authorized 
by the FDA because three-parent IVF has not been authorized to be used on human beings 
in the United States. Id.  
Mary A. Malarkey, the director of the FDA’s Office of Compliance and 
Biologics Quality at the agency’s Center for Biologics Evaluation and 
Research, said Zhang had submitted a written request dated April 22, 2016, 
“asking for a pre-investigational new drug (IND) meeting for a clinical 
investigation of a ‘spindle transfer for assisted pregnancy in patients with 
mitochondrial disease.’” 
Id. The FDA rejected the request citing “Congress’ prohibition on the use of funds to accept 
IND submissions for clinical investigations that involve a human embryo being 
‘intentionally created or modified to include a heritable genetic modification.’” Id.  
9 Susan Scutti, First Three-Parent Baby Girl Born Using Controversial IVF Technique, CNN 
(Jan. 18, 2017, 4:08 PM), https://www.cnn.com/2017/01/18/health/ivf-three-parent-baby-
girl-ukraine-bn/index.html. The sex of the embryo could have significant ramifications, 
which has sparked an ethical debate. Id. Doctors in Kiev, Ukraine, helped a previously 
infertile couple conceive and deliver a baby girl using three-parent IVF. Id. According to 
Lori P. Knowles, adjunct professor at the University of Alberta School of Public Health, 
skeptics are arguing that if three-parent IVF is going to be utilized, it should be limited to a 
male embryo. Id. A male baby “carrying donor mitochondria cannot pass their modified 
genetics onto any future children they may have because once a sperm fuses with an egg to 
form an embryo, the masculine mitochondrion withers and dies leaving the resulting embryo 
with only mitochondrion from the mother’s egg.” Id. Speaking about the baby girl born in 
Ukraine, Ms. Knowles states: “I do think it’s highly significant that this is a girl because we 
know for sure that she will be passing on her mitochondrial DNA through her maternal 
line[.]” Id.  
10 Id.  
11 Assisted Reproductive Technology, MEDLINE PLUS, https://medlineplus.gov/assistedrepro 
ductivetechnology.html (last visited Feb. 24, 2018).  
12 Id. 
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Most people have heard about regular IVF, which is a procedure designed to 
assist women who have fertility issues to become pregnant through egg 
donation.13 Although the mother bears the child,14 she is not genetically 
related to the child, as the egg comes from a third-party donor. Three-parent 
IVF provides a remedy for women with fertility issues who long to be 
genetically related to their child. 
This Comment will discuss the two different infertility-causing 
conditions that can be remedied by mitochondrial transplants: “aged eggs”15 
and mitochondrial disease.16 Three-parent IVF remedies both issues for 
women by allowing the mother to receive assistance from a donor while 
maintaining a genetic bond with her child. The three-parent IVF procedure 
essentially results in a child with three genetic parents, hence its name.17 
Exciting as it may sound, three-parent IVF is currently not allowed in the 
                                                     
13 In Vitro Fertilization (IVF), JOHNS HOPKINS MED., http://www.hopkinsmedicine.org 
 /fertility/services /ivf/index.html (last visited Feb. 24, 2018). 
14 Bearing, MERRIAM-WEBSTER, https://www.merriam-webster.com/dictionary/bearing (last 
visited Feb. 24, 2018) (meaning “the act, power, or time of bringing forth offspring”).   
15 Aging Eggs: Exciting Research is on the Horizon, FERTILITY AUTHORITY, https://www.f 
ertilityauthority.com/articles/aging-eggs-exciting-research-horizon(last visited Feb. 24, 
2018). Aging takes a toll on the human body and a female’s eggs are no exception: 
We get tired as we age, and so do our eggs—the oocytes don’t have enough 
energy to go through the rapid cell division for fertilization. It becomes 
harder to get pregnant naturally and through fertility treatments such as in 
vitro fertilization (IVF). These aging eggs are more likely to have 
chromosomal abnormalities known as aneuploidy, less likely to develop 
into embryos once fertilized, and if they do develop, they are more likely 
to not implant or be lost through miscarriage. 
Id. 
16 Mitochondrial Disease, MEDICINENET.COM, https://www.medicinenet.com/mitochondrial 
_disease/article.htm (last visited Nov. 26, 2017). Mitochondrial disease greatly affects the 
human body’s ability to function properly: 
Mitochondrial disease includes a group of neuromuscular diseases caused 
by damage to intracellular structures that produce energy, the 
mitochondria. . . . Mitochondrial myopathies are a group of neuromuscular 
diseases caused by damage to the mitochondria—small, energy-producing 
structures that serve as the cells’ “power plants.” Nerve cells in the brain 
and muscles require a great deal of energy, and thus appear to be 
particularly damaged when mitochondrial dysfunction occurs. 
Id. 
17 Bob Zhao, Mitochondrial Replacement Therapy and the Regulation of Reproductive 
Genetic Technologies in the United States, 15 DUKE L. & TECH. REV. 121, 123 (2017). 
Three-parent IVF results in DNA from the mother and father, along with the mitochondrial 
DNA from the donor. Id.   
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United States. The global discussion about three-parent IVF is on the rise, as 
the United Kingdom has recently passed legislation to allow the procedure.18 
This rise in global awareness gives the United States a prime opportunity to 
take a hard look at the procedure. The question then becomes: What is the 
liability associated with three-parent IVF procedures when the inevitable first 
injury occurs within the United States?  
 Consider the following hypothetical: John and Mary have been 
married for 18 years and are interested in starting a family together. They are 
both in their late 40s, and Mary has enjoyed a career as an attorney for the 
last 15 years. Mary made the conscious choice to pursue a career before 
establishing a family, but that choice has put her in a difficult position. Her 
mtDNA is defective due to her age (“aged eggs”19), and as a result, she will 
likely be unable to become pregnant. Mary yearns to be genetically attached 
to her child, so she rules out regular IVF and adoption. John, a physician, 
hears about three-parent IVF through a colleague and decides to look into it. 
He contacts a fertility specialist who performs three-parent IVF procedures, 
and the specialist informs them of a new clinical trial that was just approved. 
John and Mary meet with the fertility specialist, who is willing to perform the 
procedure. Mary signs an informed consent form to go ahead with the 
procedure; during the procedure, the fertility specialist makes crucial 
mistakes, causing serious complications with the embryo. The child is born 
with multiple issues—all attributable to the fertility specialist’s failure to use 
reasonable care in the process. John and Mary are now wondering what the 
fertility specialist’s liability for the procedure will be if they file a medical-
malpractice lawsuit against him. 
 The purpose of this Comment is to explore the relationship between 
three-parent IVF and medical malpractice in the United States. The first 
section begins with a basic scientific overview of three-parent IVF. It then 
transitions into the current professional standards pertaining to care and 
informed consent—primarily as they apply to the doctor-patient relationship. 
A discussion follows in the third section regarding the current regulatory 
climate for safety within the human-based product industry and within the 
medical profession itself. This Comment concludes by proposing the 
                                                     
18 Kate Kelland, For the First Time, U.K. Allows Clinic to Proceed with “3-Parent” Baby 
Procedure, SCI. AM. (Mar. 16, 2017), https://www.scientificamerican.com/article/for-the- 
first-time-u-k-allows-clinic-to-proceed-with-3-parent-baby-procedure/.   
19 See supra note 15 and accompanying text. 
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implementation of three-parent IVF as a clinical trial so that physicians, 
scientists, and researchers can monitor risks and outcomes. If the resulting 
empirical evidence is satisfactory to legislators, the eventual goal is to fully 
legalize the procedure in the United States—offering three-parent IVF to 
patients who cannot utilize regular IVF or other means to satisfy their fertility 
needs. This Comment recommends that the evidence-based standard of care 
should be adopted, along with the reasonable patient standard of informed 
consent, when it comes to dealing with three-parent IVF procedures in the 
United States. Lastly, this Comment addresses the need to establish a fertility 
court to assist injured plaintiffs in medical-malpractice lawsuits involving 
three-parent IVF procedures. 
I. THE SCIENCE 
A. An Overview of Three-Parent IVF 
  “The field of reproductive technology is renowned for pushing 
boundaries and contributing innovative approaches to the pursuit of fertility 
enhancement.”20 Robert Edwards21 was the recipient of a Nobel Prize in 
physiology and medicine for pioneering IVF—a procedure that ultimately 
helped alleviate the mental and emotional pain associated with infertility.22 
Unprecedented scientific breakthroughs are transforming reproductive 
medicine as we know it.23 Human germline genetic modification (HGGM) 
                                                     
20 Zhao, supra note 16, at 121. 
21 Robert Edwards was a fertility medicine pioneer, making many significant contributions 
throughout his career—culminating in a Nobel Prize:  
Sir Robert Geoffrey Edwards [was a] British medical researcher who 
developed the technique of in vitro fertilization (IVF). Edwards, together 
with British gynecologist Patrick Steptoe, refined IVF for the human egg. 
Their work made possible the birth of Louise Brown, the world’s first 
“test-tube baby,” on July 25, 1978. Edwards was awarded the 2010 Nobel 
Price for physiology or Medicine for his discoveries. 
Robert Edwards: British Medical Researcher, ENCYCLOPEDIA BRITANNICA, https://  
www.britannica.com/bio graphy/Robert-Edwards (last visited Feb. 24, 2018).  
22 Eli Y. Adashi, Fifty Years After Huxley: The Roadmap of Reproductive Medicine Revisited 
and Updated: The 2015 SRI-Pardi Distinguished Scientist Plenary Lecture of the Society of 
Reproductive Investigation, 22 REPROD. SCI. 1330, 1330 (2015). 
23 Id.  
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has the potential to play an instrumental role in these breakthroughs by 
altering genes in sperm and embryos24 in fertility treatment.25  
[HGGM] means deliberately changing the genes passed on to 
children and future generations – in other words, creating 
genetically modified people. [HGGM] has for many years 
been widely considered off-limits, for both safety and social 
reasons. It is formally prohibited in more than 40 countries.26 
 The human body is comprised of cells, each containing 46 
chromosomes of DNA that provide the blueprint for the cell’s development 
and function.27 Each cell contains a nucleus that houses human genetic 
material, including mitochondria, which act as the cell’s “battery pack,” using 
oxygen to create energy that powers the cell.28 Each cell contains mtDNA.29 
                                                     
24 Embryo, FREE DICTIONARY, https://medical-dictionary.thefreedictionary.com/embryo  
(last visited Feb. 24, 2018). The definition of an embryo is as follows:  
[A] new organism in the earliest stage of development. In humans this is 
defined as the developing organism from the fourth day after fertilization 
to the end of the eighth week. After that the unborn baby is usually referred 
to as the fetus. . . . Immediately after fertilization takes place, cell division 
begins and progresses at a rapid rate. At approximately 4 weeks the cell 
mass becomes a recognizable embryo from 7 to 10 mm long with 
rudimentary organs. The beginnings of the eyes, ears, and extremities can 
be seen. By the end of the second month the embryo has grown to a length 
of 2 to 2.5 cm, and the head is the most prominent part because of the rapid 
development of the brain; the sex can be distinguished at this stage. At the 
time of fertilization the ovum contains the potential beginnings of a human 
being. As cell division takes place the cells of the blastoderm (embryonic 
disk) gradually form three layers from which all the body structures 
develop. The ectoderm (outer layer) gives rise to the epidermis of the skin 
and its appendages, and to the nervous system. The mesoderm (middle 
layer) develops into muscle, connective tissue, the circulatory organs, 
circulating lymph and blood cells, endothelial tissues within the closed 
vessels and cavities, and the epithelium portion of the urogenital system. 
From the endoderm (internal layer) are derived those portions not arising 
from the ectoderm, the liver, the pancreas, and the lungs. 
Id. 
25 Zhao, supra note 16, at 121–22. 
26 About Human Germline Gene Editing, CTR. FOR GENETICS & SOC’Y (July 9, 2015), 
https://www.geneticsand society.org/internal-content/about-human-germline-gene-editing. 
27 J. Ravindra Fernando, Note, Three’s Company: A Constitutional Analysis of Prohibiting  
Access to Three-Parent In Vitro Fertilization, 29 NOTRE DAME J.L. ETHICS & PUB. POL’Y 
523, 528 (2015). 
28 Id. 
29 Ruth L. Fischbach et al., Creating a Three-Parent Child: An Educational Paradigm for 
 the Responsible Conduct of Research, 15 J. MICROBIOLOGY & BIOLOGY EDUC. 186, 186 
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 “Mitochondria are ‘responsible for providing more than 90% of the energy 
needed by the body to sustain life and support growth.’”30 
In reproduction, the egg and the sperm each carry half of the required 
number of chromosomes and combine their nuclear DNA (nDNA)31 to create 
a zygote,32 which divides to form an embryo.33 MtDNA, however, is unique 
in that it is not created by a combination of the parents’ DNA.34 Instead, 
individuals inherit mtDNA exclusively from their mothers.35 Although 
mtDNA accounts for a very small percentage of the human genome, 
mitochondrial gene mutations can cause severe neurological consequences.36 
“Mitochondrial dysfunction has been recognized as a significant cause of a 
number of serious multi-organ diseases. Tissues with a high metabolic 
demand such as brain, heart, muscles, [and central nervous system] CNS are 
often affected.”37 Health conditions that arise out of mitochondrial disease 
can be due to mutations in mtDNA or in nuclear genes involved in 
mitochondrial function.38 Mitochondrial disease may contribute to many 
common and serious illnesses such as Alzheimer’s, Parkinson’s, diabetes, 
arthritis, cancer, and premature aging.39 “There is no curative treatment for 
patients with mitochondrial disease, [and] given the lack of treatments and 
the limitations of prenatal and preimplantation diagnosis, attention has 
focused on prevention of transmission of mitochondrial disease through 
                                                     
(2014). 
30 Nicole Baffi, The Good, The Bad, and the Healthy: How Spindle-Chromosomal Complex 
Transfer Can Improve the Future, 74 ALB. L. REV 361, 363 (2010). 
31 Difference Between Mitochondrial DNA and Nuclear DNA, MAJOR DIFFERENCES, http:// 
 www.majordifferences.com/2015/05/difference-between-mitochondrial-dna.html#.WhhZ- 
kyZPgo (last visited Feb. 24, 2018). Nuclear DNA (nDNA) makes up approximately 93% of 
the total DNA in a human being. Id. It is made up of 3.3 billion DNA base pairs and codes 
for all proteins required for its function. Id. nDNA is inherited equally between the parents, 
unlike mtDNA, which is only inherited from the maternal line. Id. 
32 Zygote, COLLINS, https://www.collinsdictionary.com/us/dictionary/english/zygote (last 
visited Feb. 24, 2018) (“A zygote is an egg that has been fertilized by sperm, and which  
could develop into an embryo.”).  
33 ASSOC. OF REPROD. HEALTH PROF’LS, HUMAN CLONING AND GENETIC MODIFICATION: 
THE BASIC SCIENCE YOU NEED TO KNOW 5, http://www.arhp.org/uploadDocs/cloning.pdf. 
34 Fischbach et al., supra note 29, at 187. 
35 Fernando, supra note 27, at 529.  
36 Fischbach et al., supra note 29, at 187. 
37 Paula Amato et al., Three-Parent IVF: Gene Replacement for the Prevention of Inherited 
Mitochondrial Diseases, NAT’L CTR. FOR BIOTECHNOLOGY INFO. (Jan. 1, 2015), https://ww 
 w.ncbi.nlm.nih.gov/pmc/articles/PMC4005382/. 
38 Id.  
39 Baffi, supra note 30, at 361.  
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[HGGM] therapy.”40  MtDNA mutations are difficult to identify within the 
mother’s eggs because of the mutation’s inconsistent and erratic 
nature.41 This has created a considerable challenge to find ways to prevent 
mutated mtDNA from genetically transferring to the child.42 Approximately 
1 in 4,000 children are born in the U.S. with an inherited mitochondrial 
disease.43 
B. Mitochondrial Replacement Therapy 
Mitochondrial Replacement Therapy (MRT) is an experimental ART 
for women with “aged eggs”44 or mitochondrial disease who want to avoid 
passing the disease to their children.45 Essentially, MRT involves transferring 
DNA between two fertilized eggs, creating a new embryo containing the core 
nDNA from the mother and father and the healthy mtDNA from a female egg 
donor.46 This therapy results in a child with DNA from three different 
people.47 There are two methods by which MRT can be performed: the 
pronuclear transfer method and the maternal spindle transfer method.48 
1. Pronuclear transfer method. The pronuclear transfer method 
involves removal of genetic material from an embryo created from the donor 
sperm and egg, which is then replaced with genetic material from a second 
embryo created from the paternal sperm and egg.49 First, the mother’s egg 
(with mitochondrial disease) is fertilized with the father’s sperm, creating an 
embryo.50 Second, the donor egg is fertilized with donor sperm and the nDNA 
is removed—leaving behind the donor’s healthy mitochondria and also 
creating an embryo.51 The final step is to transfer the nDNA from the 
mother’s embryo to the donor embryo where the healthy mitochondria 
                                                     
40 Amato et al., supra note 37.  
41 Baffi, supra note 30, at 362. 
42 Id.  
43 Amato et al., supra note 37.  
44 See supra note 15 and accompanying text. 
45 See supra note 15 and accompanying text.  
46 Padmini Cheruvu, Three-Parent IVF and Its Effect on Parental Rights, 6 HASTINGS SCI. 
& TECH. L.J. 73, 76 (2014). 
47 Amy B. Leiser, Note, Parentage Disputes in the Age of Mitochondrial Replacement 
Therapy, 104 GEO. L.J. 413, 414 (2016). 
48 Id. at 420. 
49 Cheruvu, supra note 46.  
50 Id. 
51 Id. 
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remains.52 This provides a viable, healthy embryo with the nDNA of the 
mother and father and the mtDNA of the donor.53 
2. Maternal spindle transfer method. Dr. Zhang, from New 
Hope Fertility Center in New York, utilized the maternal spindle transfer 
method (MST) for the Jordanian couple.54 
[MST] involves placing nuclear material from the mother’s 
egg into a donor egg “shell,” which contains healthy 
mitochondria but no nDNA. In this method the egg is 
fertilized with the father’s sperm in vitro, but not until after 
the transfer occurs. Since an unfertilized egg is more 
susceptible to damage, researchers believe that the more 
complex pronuclear transfer method, which involves two in 
vitro fertilizations, will be the preferred, future technique.55 
The medical profession is highly regarded because of the significant 
role it plays in the well-being of society. This high regard comes with high 
standards: the imposition of heightened standards of care and informed 
consent on the medical industry. Pronuclear transfer and maternal spindle 
transfer are both methods used in three-parent IVF procedures that require 
great care and diligence from the medical professionals administering the 
procedures to patients. This next section will discuss those standards and how 
they pertain to three-parent IVF. 
II. PROPER STANDARDS OF CARE AND INFORMED CONSENT FOR 
MEDICAL PROCEDURES 
 Medical professionals are held to high standards, but those standards 
are not always adequate for every medical procedure. There is a standard of 
care that is practically universal to all physicians in the United States: the 
customary care model.56 But, is this model sufficient for three-parent IVF 
procedures? And, what role the patient should play when deciding for or 
against a certain medical procedure? These are questions that must be 
answered, especially within the context of three-parent IVF. 
                                                     
52 Tina Hesman Saey, How to Make a ‘Three-Parent’ Baby: Scientists Combined an Egg, 
 Sperm and Some Donor DNA to Create a Baby, SCI. NEWS FOR STUDENTS (Feb. 21, 2017 
7:10 AM), https://www.sciencenewsfor students.org/article/how-make-three-parent-baby. 
53 Id.  
54 Liat Clark, Three-Parent Babies: How are They Made and is the IVF Legal?, WIRED 
(Jan. 18, 2017), http://www.wired.co.uk/article/what-is-three-person-ivf. 
55 Cheruvu, supra note 46, at 76 (footnotes omitted). 
56 BARRY R. FURROW ET AL., HEALTH LAW 265 (2nd ed. 2000). 
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A. The Standards of Care in the United States 
Judges and juries do not establish the standards by which medical 
services are to be delivered to the public.57 In fact, these standards are created 
solely by the medical professionals themselves, and courts simply enforce 
these standards in lawsuits.58 A plaintiff has the burden to prove that the 
doctor breached the standard of care, and most courts give conclusive weight 
to that standard.59 
 Tom Baker, author of The Medical Malpractice Myth, states his 
opinion relating to the seriousness of having correct standards of care in 
place: 
One very clear conclusion emerges from the research on 
medical malpractice and medical malpractice lawsuits: The 
real medical malpractice problem is medical malpractice. It is 
not pretty to say, but doctors and nurses make preventable 
mistakes that kill more people in the United States every year 
than workplace and automobile accidents combined. Any 
research-driven approach to medical liability reform must 
start with this fact firmly in mind.60 
This section will discuss the two standard of care models: the customary care 
standard and the evidence-based standard. 
 Doctors are liable when they make certain mistakes. Society generally 
demands that a doctor not be immune from liability to ensure quality 
healthcare delivery. The customary care standard is used throughout the 
country to determine a doctor’s liability.61 This custom-based standard of 
care is the requisite degree of both care and skill, based on the medical 
knowledge available, that a PR actioner in a provider’s specialty must 
demonstrate.62 “Custom-based medical practice can have a profoundly 
negative impact on the quality and cost of healthcare. . . . The customary care 
(or eminence-based) model of medical practice is based on physician 




60 TOM BAKER, THE MEDICAL MALPRACTICE MYTH 157 (reprt. 2007). 
61 Katharine Van Tassel, Harmonizing the Affordable Care Act with the Three Main National 
Systems for Healthcare Quality Improvement: The Tort, Licensure, and Hospital Peer 
Review Hearing Systems, 78 BROOK. L. REV. 883, 884 (2013). 
62 David Goguen, What is the Medical Standard of Care?, ALLLAW, http://www.alllaw. 
com/articles/nolo/medical-malpractice/standard-of-care.html (last visited Feb. 24, 2018). 
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preference grounded in tradition, opinion, or clinical experience and not on 
objective, scientific evidence.” 63 Conversely, the evidence-based standard of 
care can have a positive impact on the quality and cost of healthcare because 
it includes research, clinical expertise, and patient preferences and values.64 
There are five ways that the evidence-based standard benefits the 
healthcare system as a whole: (1) it helps physicians stay up-to-date on 
standardized protocols that are evidence-based; (2) the standard requires near 
real-time data for physicians to make health care decisions; (3) it promotes 
transparency and accountability; (4) it improves the overall quality of care 
administered; and (5) it has better clinical outcomes.65 Dr. John Haughom, 
senior advisor of Health Catalyst University, described the necessary and 
proper steps to be taken in evidence-based medicine.66 First, teams of 
physicians must identify problems that need to be addressed, such as reducing 
                                                     
63 Van Tassel, supra note 61.  
64 John Haughom, 5 Reasons the Practice of Evidence-Based Medicine is a Hot Topic, 
HEALTHCATALYST, https://www.healthcatalyst.com/5-reasons-practice-evidence-based-me 
dicine-is-hot-topic (last visited Feb. 24, 2018). The evidence-based standard of care brings 
more efficiency to the healthcare system by incorporating meaningful patient involvement: 
Practicing evidence-based medicine is important in today’s healthcare 
environment because this model of care offers clinicians a way to achieve 
the Triple Aim’s objectives of improved quality, improved patient 
satisfaction, and reduced costs. To understand how, consider the prostate 
cancer example. With evidence-based medicine, a provider can assess the 
strength of the evidence as well as the risks and benefits of ordering 
diagnostic tests and treatments for each cancer patient. Such an approach, 
couples with the provider’s clinical experience, enables the provider to 
better predict if a treatment will do more harm than good. It also helps the 
organization establish a systematic approach to caring for patients with 
specific conditions . . . . As reported in the article “The Importance and 
Impact of Evidence-Based Medicine,” using evidence-based medicine 
“help[s] physicians provide more rational care with better outcomes.” 
Evidence-based medicine is not just about using evidence to design 
treatment plans; It also encourages a dialogue between patients and 
providers, so patients can share in the decision-making and make their 
values and preferences known. Together, patient and provider can 
determine an appropriate course of action—or no course of action if that’s 
on the joint decision. The benefit of this approach is that providers listen to 
patient concerns and take them into consideration to determine the 
appropriate treatment plan. 
Id. 
65 Id.  
66 Id.  
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readmissions or some other high-priority problem.67 Some questions that 
physicians can ask themselves are: Why are we practicing in this manner? 
Are we adhering to best practices, and can we produce better outcomes with 
more consistency? Second, the physicians must acquire the best possible 
evidence that is available to them. 
There are many different sources of evidence—from the 
knowledge clinicians gain from treating their patient 
populations to new research being discovered from highly 
organized randomized controlled trials (RCTs). . . . To help 
clinicians compare the quality between the various sources 
of evidence, Dr. David Sackett, MD, popularized the 
evidence-based medicine pyramid.68 
The evidence-based medicine pyramid recognizes four types of evidence that 
physicians must wade through to find the best information out there.69 Third, 
Dr. Haughom notes that the physician must appraise the evidence to make 
sure it is applicable to the patient(s) being considered.70 Fourth, the physician 
applies the evidence to her practice of medicine on a regular basis.71 “If the 
evidence passes the appraisal step and adds value to the practice of medicine, 
then clinicians can incorporate the new knowledge into their daily clinical 
practice.”72 Finally, the physician must assess her performance to ensure that 
best outcomes are being consistently achieved.73 An evidence-based standard 
of care that follows these steps can lower medical costs and help achieve more 
efficient patient care in the United States.74 Three-parent IVF, along with 
                                                     
67 Id. 
68 Id. (“[In the evidence-based pyramid,] the top level is the strongest because it underwent 
a systematic review process and meta-analysis. Evidence in the lowest is the weakest because 
it is primarily based on opinions and small sample sizes, which increases room for error.”). 
69 Id. The levels of evidence in the evidence-based pyramid are as follows: The first level is 
considered to be “the gold standard,” RCTs. Id. These RCTs are “free from any bias that 
might otherwise be introduced by the people involved.” Id. Level two consists of evidence 
from controlled trials without randomization and other relevant studies. Id. This level is not 
as reliable as the first level, but is still quite reliable. Id. The third level of evidence is based 
largely on expert opinions and has a large margin for errors. Id. The fourth and final level of 
evidence on the pyramid is evidence that is based on personal experiences. Id. Level three 





74 Van Tassel, supra note 61, at 889. Professor Van Tassel argues for a shift to an evidence-
based standard of care: 
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regular IVF, requires such a standard due to the sensitive and technical nature 
of the procedure. Patients are required to sign an informed consent form for 
each and every medical procedure to be performed. That begs the question: 
What does being informed actually mean in the context of the medical 
profession? The next section deals with two different standards that exist and 
how they could affect three-parent IVF procedures in the future. 
B. Informed Consent: Paternalistic or Reasonable Patient? 
 A person’s body is her temple.75 It is a general norm in American 
society that people must consent to activities—especially those that deal with 
the body76—and visiting the doctor is no exception to that rule. 
The doctrine of informed consent developed out of strong 
judicial deference to individual autonomy, reflecting a 
prevalent belief in American jurisprudence that an individual 
has a right to be free from nonconsensual interference with 
his or her person, and a basic moral principle that it is wrong 
to force another to act against his or her will.77 
At this point, some historical perspective on how informed consent 
has evolved over the years seems proper. Jay Katz,78 physician and law 
                                                     
The last several decades of public health research have revealed that 
customary care can actually be “bad” patient care. Customary care can lead 
to misuse and underuse of the delivery of healthcare. . . . The quality and 
cost problems with the customary care model have led to new national 
initiatives to move the United States toward a modern, evidence-based 
model of medical practice . . . . 
Id. at 889, 899. 
75 1 Corinthians 6:19 (“Do you not know that your body is a temple of the Holy Spirit who 
is in you, whom you have received from God? You are not your own.”). 
76 Schloendorff v. Soc’y of New York Hosp., 211 N.Y. 125, 129 (1914) (“Every human being 
of adult years and sound mind has a right to determine what shall be done with his own 
body.”). 
77 FURROW ET AL., supra note 56, at 310. 
78 Yale Law School Mourns Professor Jay Katz; Read Dean Koh Memorial Remarks, YALE 
L. SCH. (Nov. 17, 2008), https://law.yale.edu/yls-today/news/yale-law-school-mourns-prof 
essor-jay-katz-read-dean-koh-memorial-remarks. Yale Law School held a memorial service 
in Jay Katz’ memory and an article was written detailing his remarkable life: 
[Jay Katz] graduated from the University of Vermont in 1944, and earned 
an M.D. from Harvard Medical School in 1949. After completing his 
internship and residency in New York, Katz served as 1st Lieutenant and 
Captain at the USAF Hospital at Maxwell Air Force Base in Alabama. He 
came to Yale in 1953 and was soon named Chief Resident of the outpatient 
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professor, authored The Silent World of Doctor and Patient. He stated: 
“[D]isclosure and consent, except in the most rudimentary fashion, are 
obligations alien to medical thinking and practice.”79 Historically, the 
standards of consent primarily served as the basis for physicians to impose 
their will, essentially forcing the patients to agree with their physicians’ 
treatment plans.80 The judiciary created the doctrine of informed consent, 
which moved, according to Katz, through three distinct eras of evolution 
before reaching its modern iteration.81 The first era simply required the 
physician to tell the patient which course of treatment would be taken and 
nothing more.82 This era can be roughly traced to the mid-twentieth century.83 
The second era of informed consent saw the arrival of patient inclusion, 
requiring physicians to give patients alternative treatment options along with 
any risks associated with those options.84 This era lasted until the early 
1970s.85 The third era—the current state of informed consent—has changed 
very little from the previous one, in that physicians are required to give 
patients all available treatment options and all accompanying risks.86 
 The first case to mention informed consent was Salgo v. Leland 
Stanford Jr. University Board of Trustees in 1957.87 Justice Bray stated in the 
majority opinion: 
A physician violates his duty to his patient and subjects 
himself to liability if he withholds any facts which are 
necessary to form the basis of an intelligent consent by the 
patient to the proposed treatment. A physician may not 
                                                     
clinic at the School of Medicine. Katz began teaching psychiatry at Yale in 
1955 and psychiatry and law in 1958 when he was named Assistant 
Professor of Psychiatry and Law at Yale University. . . . He was a leader in 
the area of reproductive technology law and ethics and was an outspoken 
opponent of the criminal prosecution of pregnant women, citing privacy 
and equal protection concerns. 
Id. 
79 FURROW ET AL., supra note 56, at 311 (quoting JAY KATZ, THE SILENT WORLD OF DOCTOR 
AND PATIENT 1 (1984)). 
80 Id.  
81 Id.  
82 Id.  
83 Id.  
84 Id.  
85 Id. 
86 Id.  
87 See generally Salgo v. Leland Stanford Jr. Univ. Bd. of Tr., 154 Cal.App.2d 560 (1957).   
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minimize the known dangers of a procedure or operation in 
order to induce his patient’s consent.88 
Generally speaking, the disclosure requirement means physicians must 
inform the patient of all available treatment options and any risks and benefits 
associated with them.89 Further, it must include any alternative treatment 
options that are available, as well as the potential risks and benefits that flow 
from those alternatives.90 Lastly, it is essential to include the option of no 
treatment at all, followed by a similar risk-benefit analysis.91 
There are two models of informed consent, and they conflict with one 
another. The first standard is known as the “paternalistic” or physician-based 
standard, which is closely related to the customary care model.92 It is 
grounded in profession uniformity and physician preference.93 The second 
standard is known as the “reasonable patient” standard, where the patient’s 
values and preferences are integrated into the decision-making process.94 
1. Physician-based standard, a.k.a. the paternalistic standard. 
A majority of states have adopted the physician-based standard as the 
standard for the disclosure requirement of informed consent.95 It is rooted in 
the notion that the medical practice field needs to be uniform and consistent 
so that doctors are able to advance their patients’ best interests in the most 
efficient and safe manner possible.96 It requires expert testimony so doctors 
do not need to concern “themselves with the risk that an uninformed lay jury 
will later decide they acted improperly.”97 The majority of jurisdictions that 
have adopted this as the standard to disclosure require a plaintiff to show two 
things: that a reasonable doctor similarly situated would make the disclosure, 
and that the doctor did not comply with this standard.98 
                                                     
88 Id. at 578. 
89 Suzanne K. Ketler, Note, The Rebirth of Informed Consent: A Cultural Analysis of the 
Informed Consent Doctrine After Schreiber v. Physicians Insurance Co. of Wisconsin, 95 
NW. U. L. REV. 1029, 1037 (2001). 
90 Id.  
91 Id.  
92 FURROW ET AL., supra note 56, at 313. 
93 Id. 
94 Id. at 314. 
95 Id. 
96 Id. at 313. 
97 Id. 
98 Id. at 314. 
218 CONCORDIA LAW REVIEW Vol. 3 
 
2. Reasonable patient standard. The reasonable patient standard 
rebuts the majority view. The landmark case, Canterbury v. Spence, held that 
the reasonable patient standard was the most effective standard, with the court 
stating that “[w]e do not agree that the patient’s cause of action is dependent 
upon the existence and nonperformance of a relevant professional 
tradition.”99 The Canterbury court emphasized that each patient has specific 
needs that are distinct and separate from other patients—thus the need for a 
reasonable patient disclosure standard.100 In Wheeldon v. Madison, the court 
concluded that the physician-based standard may conflict with the patient’s 
specific needs.101 The Wheeldon court stated: “[W]e adopt the Canterbury v. 
Spence rule that the standard measuring the performance of the physician’s 
duty to disclose is conduct which is reasonable under the circumstances.”102 
Even though the physician-based standard is currently followed by a majority 
of states, the reasonable patient standard is quickly approaching a majority 
position.103 
III. CURRENT CLIMATE FOR SAFETY REGULATION IN THE UNITED STATES 
Three-parent IVF requires the use and manipulation of human-based 
products; therefore, great care and diligence are required to ensure patient 
safety. There are many federal agencies that oversee the human-based 
product industry to make sure that safety is the number one priority of 
medical providers. 
The process of administering three-parent IVF, or regular IVF for that 
matter, requires multiple steps and has many different layers of safety 
regulation. First, there are technologies (such as devices and software) used 
in fertility treatment that are governed by the FDA.104 It also regulates the 
safety of tissue-based products, including donated eggs and semen.105 
Second, there are laboratory tests performed on human tissues (such as eggs 
and semen), which are governed under the Clinical Laboratory Improvement 
Amendments (CLIA).106 Third, there are safety regulations in place for 
techniques in the practice of medicine that are regulated by the individual 
states under their police powers.107 Since safety is always a top priority when 
                                                     
99 Canterbury v. Spence, 464 F.2d 772, 783 (D.C. Cir. 1972). 
100 Id. 
101 Wheeldon v. Madison, 374 N.W.2d 367, 374 (S.D. 1985). 
102 Id. 
103 FURROW ET AL., supra note 56, at 314. 
104 See infra Part III.A. 
105 See infra Part III.A. 
106 See infra Part III.B. 
107 See infra Part III.C. 
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it comes to performing medical procedures, current safety regulations must 
be applied to three-parent IVF.  
A. FDA Safety Regulations for Human-Based Products 
The regulation of reproductive technologies seems to be an area from 
which the law tends to shy away: history has revealed that regulating 
reproductive health is a particularly sensitive topic.108 At first glance, 
reproductive technologies regulation seems to be something that should fall 
to the individual states so they can protect their citizens’ health and 
welfare.109 However, states rarely oversee reproductive technologies. The 
FDA is responsible for safety regulation under the Public Health Service Act 
(PHSA), which means the FDA regulates reproductive technologies, not the 
individual states themselves.110 
Three-parent IVF would fall directly under the FDA’s safety 
regulations because the procedure deals with human-based products—semen 
and eggs—that are manipulated in laboratories.111 Proper screening protocols 
for eligible patients and donors is of paramount importance to avoid the 
spread of communicable diseases. The FDA regulates safety in all of these 
areas. 
The FDA currently regulates human tissue-based products,112 which 
consist of the following: “human cells or tissue intended for implantation, 
transplantation, infusion, or transfer into a human recipient.”113 Examples of 
human tissue that fit within the FDA’s regulatory responsibility are “bone, 
skin, corneas, ligaments, tendons, dura mater, heart valves, hematopoietic 
stem/progenitor cells, . . . oocytes, and semen.”114 
The purpose of FDA tissue regulation is “to create an electronic 
registration and listing system for establishments that manufacture human 
cells, tissues, and cellular and tissue-based products . . . and to establish 
                                                     
108 See Lawrence v. Texas, 539 U.S. 558 (2003); Bellotti v. Baird, 443 U.S. 622 (1979); Roe 
v. Wade, 410 U.S. 113 (1973); Griswold v. Connecticut, 381 U.S. 479 (1965). 
109 Tandice Ossareh, Would You Like Blue Eyes with That? A Fundamental Right to Genetic 
Modification of Embryos, 117 COLUM. L. REV. 729, 734–35 (2017). 
110 Id. at 735. 
111 Id. 
112 Tissue and Tissue Product Questions and Answers, U.S. FOOD & DRUG ADMIN. (Feb.  
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donor-eligibility, current good tissue practice, and other procedures to 
prevent the introduction, transmission, and spread of communicable diseases 
by [tissue-based products].”115 It will be imperative that three-parent IVF 
donors and patients alike are adequately screened for eligibility. This safety 
regulation will help form the basis for the screening protocol for three-parent 
IVF procedures. The FDA should look to current screening protocols in place 
for regular IVF when deciding proper protocols to implement for three-parent 
IVF. 
The FDA takes a risk-based approach to its regulation of tissue-based 
products with three goals in mind.116 First, the regulation seeks to “limit[] the 
risk of transmission of communicable disease from donors to recipients.”117 
Second, it “establish[es] manufacturing practices that minimize the risk of 
contamination.”118 Finally, it “requir[es] an appropriate demonstration of 
safety and effectiveness for cells and tissues that present greater risks due to 
their processing or their use.”119 Limiting the transmission of communicable 
diseases and lowering the risk of contamination will be important goals when 
dealing with three-parent IVF. The procedure is quite invasive and 
technical—even more technical than regular IVF. Therefore, these three 
goals should be of the utmost importance for the FDA when determining a 
risk level to associate with three-parent IVF. 
The main objective and focus for the FDA is to limit the transmission 
of communicable diseases. It is with this objective in mind that it applies 
safety regulations to the human tissue-based product industry. Three-parent 
IVF should and will be required to meet all FDA regulations and guidelines 
in order to ensure patient safety. 
B. Procedures Performed in Laboratories are Governed by CLIA 
Human-based products are regulated and screened for safety by the 
FDA, but the regulation does not stop there. These human-based products are 
manufactured and manipulated inside medical laboratories, and there are 
separate regulations applied to these individual laboratories under CLIA. This 
section will discuss these laboratory safety regulations and their importance 
to three-parent IVF. 
                                                     
115 21 C.F.R. § 1271.1 (West 2016). 
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The world is seeing a rapid advancement in technology, and its reach 
has broad implications. Health care delivery is turning to a model of 
“personalized medicine,” which fosters more predictability and efficiency.120 
“U.S. laboratories that process human samples for health care treatment or 
prevention are subject to federal, state, and professional organization 
standards and regulations.”121 Although CLIA is the federal regulatory 
standard, it does not preempt heightened state standards.122 If a state chooses 
to implement standards that exceed CLIA, it is free to do so without objection 
from the federal regulatory bodies.123 
Diagnostic testing helps health care providers screen for or 
monitor specific diseases or conditions. It also helps assess 
patient health to make clinical decisions for patient care. . . . 
[CLIA] regulate[s] laboratory testing and require[s] clinical 
laboratories to be certificated by their state as well as the 
Center for Medicare and Medicaid Services (CMS) before 
they can accept human samples for diagnostic testing. 
Laboratories can obtain multiple types of CLIA certificates, 
based on the kinds of diagnostic tests they conduct.124 
The CLIA program’s main objective is to ensure both universal quality 
control over laboratory operations and the accuracy, proficiency, timeliness, 
and reliability of patient test results.125 Laboratories that are regulated by 
CLIA are defined as “clinical laborator[ies].”126 The broad definition of 
                                                     
120 MICHAEL J. MALINOWSKI & ANDREA NEAL, Regulation of Commercial Laboratories, in  




124 Clinical Laboratory Improvement Amendments (CLIA), U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssist
ance/ucm124105.htm (last visited Feb. 24, 2018). 
125 MALINOWSKI & NEAL, supra note 120, at 172. 
126 The CLIA definition of what constitutes a “clinical laboratory” is as follows: 
A facility for the biological, microbiological, serological, chemical, 
immunohematological, hematological, biophysical, cytological, 
pathological, or other examination of materials derived from the human 
body for the purpose of providing information for the diagnosis, 
prevention or treatment of any disease or impairment of, or the assessment 
of the health of, human beings. 
Id. at 171. 
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clinical laboratory includes hospitals, private physician offices, and all other 
clinical laboratories that are not engaged solely in research.127 
 Every laboratory that falls within the definition of a “clinical 
laboratory” must be CLIA certified.128 CMS is primarily responsible for 
implementing the CLIA program, but the administration of CLIA is not the 
sole responsibility of one single department.129 Instead, it is a combination of 
multiple federal agencies that are needed to administer CLIA in an efficient 
manner.130  
 The three federal agencies that help administer CLIA are CMS, FDA, 
and the Centers for Disease Control (CDC).131CMS is responsible for issuing 
laboratory certificates, collecting user fees, conducting site inspections, 
approving private accreditation organizations for performing site inspections, 
approving state exemption applications, monitoring laboratory performance, 
and publishing CLIA rules and regulations.132 FDA is responsible for 
categorizing laboratory tests based on complexity and reviewing requests for 
waivers.133 CDC is responsible for providing analysis, research, and technical 
assistance to laboratories; developing technical standards and laboratory 
practice guidelines; conducting laboratory quality improvement studies; and 
developing and distributing professional information and educational 
resources.134 CMS lacks the resources to oversee all laboratories in the United 
States, so it approves private organizations to act as CLIA accreditation 
entities.135 By statute, CMS must follow certain criteria when selecting a 
private accreditation organization.136 To date, CMS has approved only seven 
CLIA accreditation organizations.137 
CLIA regulation is not geographical in scope; in fact, geography does 
not even play any role in CLIA regulation.138 Instead, CLIA regulates on the 
                                                     
127 Id. 
128 Id. 
129 Id. at 173. 
130 Id. 




135 MALINOWSKI & NEAL, supra note 120, at 173. 
136 See 42 U.S.C.A. § 263a (e)(2)(A) i–vi (West 2012) (stating the criteria for selecting  
accreditation organizations). 
137 MALINOWSKI & NEAL, supra note 120, at 174. 
138 Id. at 175. 
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basis of its complexity model—the higher the risk, the more stringent the 
regulation.139 A laboratory seeking CLIA certification is evaluated using a 
risk scorecard that lists seven criteria.140 Based on the results from the 
complexity scorecard’s criteria, CMS will apply the requisite regulatory 
standards to that particular laboratory. Three-parent IVF will likely receive a 
high complexity score due to its invasive and technical nature, leading to 
tougher regulations. CLIA will ensure that three-parent IVF is administered 
in a safe and healthy environment each and every time. 
C. Medical Malpractice is Governed by the Individual States 
Practicing physicians are primarily regulated by their respective 
states.141 States govern and regulate the practice of medicine because it 
directly relates to the health and general welfare of their citizens.142 Fertility 
physicians who perform three-parent IVF procedures will be required to 
adhere to their states’ procedures and policies concerning the practice of 
fertility medicine.143 As mentioned before, three-parent IVF is a procedure 
                                                     
139 Id. 
140 The CLIA complexity scorecard criteria are as follows: 
(1) Knowledge: the degree of scientific and technical knowledge that is 
required to perform the test; (2) Training and experience: the degree of 
experience required for the pre-analytical, analytical, and post-analytical 
phases of the testing process; (3) Reagents and materials: the extent to 
which reagents and materials used in the test process or system are 
generally stable and reliable or require special handling, precautions, and 
storage conditions; (4) Characteristics of operational steps: the extent to 
which steps in the testing process are automatically executed and 
otherwise easily controlled or require close monitoring, special specimen 
preparation, temperature control, timing, extensive calculations, and other 
precautions; (5) Calibration, quality, and control, and proficiency testing 
materials: the stability and availability of these materials; (6) Test system 
troubleshooting and equipment maintenance: the extent to which test 
system troubleshooting is automatic or self-correcting and requires 
minimal judgment, or requires decision making and direct intervention; (7) 
Interpretation and judgment: the level or interpretation and judgment 
required to perform pre-analytic, analytic, and post-analytic processes to 
resolve problems. 
Id. at 177–79. 
141 Medical Liability and Malpractice, NAT’L CONF. ST. LEGISLATURES, http://www.ncsl.or 
g/research/financial-services-and-commerce/medical-liability-and-malpractice.aspx (last 
visited Feb. 24, 2018). 
142 Id. 
143 Id. 
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with multiple steps—each step with its own set of safety regulations.144 This 
section will discuss the steps that are necessary to provide adequate health 
care to patients and how negligence principles dominate the practice of 
medicine. 
The relationship between a doctor and patient is an intimate one. 
Patients oftentimes trust their doctor completely and, without reservation, 
agree to her recommendations regarding treatment. This surely seems logical 
because the doctor has been through medical school and is well-versed in the 
human body and its ailments. The average person is not comfortable with 
self-diagnosis, so visiting the doctor’s office is essential for health and well-
being. What happens when that trusted doctor makes a critical mistake while 
treating her patient? Is she liable for her actions? The short answer: it 
depends. 
In order to find liability, a number of factors must be present. There 
must be an adequate doctor–patient relationship.145 This relationship is 
developed by implied and express contracts between doctor and patient.146 
Doctors expressly contract with patients in many different situations, such as 
when an orthopedic surgeon expressly contracts to perform orthoscopic knee 
surgery or when an ophthalmologist expressly contracts to perform a surgery 
for cataracts. Both of these situations require the doctor and patient to enter 
into an express contract with one another, thus creating the adequate doctor–
patient relationship. Express contracts are not the only means to develop this 
doctor–patient relationship; in fact, they are not even the dominant method.147 
“The vast majority of contracts in the field between healthcare professionals 
and their patients are implied contracts.”148 For example, when a patient visits 
a doctor’s office, the patient is essentially offering to enter into a contract 
with the doctor.149 An implied contract is created once the doctor agrees to 
evaluate the patient.150 
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“The liability of health care providers is governed by general 
negligence principles. Malpractice is usually defined as unskillful practice 
resulting in injury to the patient, a failure to exercise the ‘required degree of 
care, skill and diligence’ under the circumstances.”151 Each individual state, 
not the federal government, regulates medical-malpractice claims among its 
physicians.152 
Under state law, a patient may pursue a civil claim against 
physicians or other health care providers, called medical 
liability or medical malpractice, if the health care provider 
causes injury or death to the patient through a negligent act or 
omission. To recover damages, the patient must establish: (1) 
The physician owed a duty to the patient; (2) The standard of 
care and that the physician violated that standard; (3) A 
compensable injury; and (4) The violation of the standard of 
care caused the harm suffered by the patient. 153 
Three-parent IVF claims will likely be primarily rooted in negligence 
principles, although contract claims will always persist among fertility 
plaintiffs with the lack of defined remedies available to them. 
The real problem with medical malpractice is that it is unavailable to 
a vast majority of fertility plaintiffs due to its high costs. A physician’s 
medical-malpractice insurance company will likely have a team of lawyers 
that can defend any lawsuit that comes its way. Unfortunately, the same 
cannot be said for most fertility plaintiffs. Money seems to put up an 
insurmountable barrier, due to most fertility plaintiffs’ inability to pay for the 
high cost of medical-malpractice litigation.  
Medical malpractice has far-reaching effects. Patients, and the 
healthcare industry as a whole, are greatly affected by the inefficient medical-
malpractice system in the United States.154 Patients are affected in many 
different ways, which can include reluctance to seek out medical help due to 
negligence claims towards a physician or hospital.155 Such malpractice suits 
could impede the trust and openness in the doctor-patient relationship, which 
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is foundational to the efficient delivery of healthcare in the United States.156 
Generally, physicians purchase medical-malpractice insurance, as most 
physicians do not possess the necessary resources to adequately defend a 
medical-malpractice lawsuit on their own.157 
Any and every system in the modern world seems to have a common 
overarching concern—efficiency. Dr. Ezekiel Emanuel158 believes there is an 
efficiency problem with the medical-malpractice system in the United States 
that is largely due to defensive medicine practices,159 stating that “[o]ne of 
the biggest concerns for physicians is medical malpractice. It agitates them 
so much that it is often hard for them to focus on anything else, and it is not 
hard to be sympathetic to their concerns.”160 Dr. Emanuel goes on to say, 
“[m]any physicians are convinced that the high rate of medical-malpractice 
suits encourage high levels of defensive medicine and excessive costs, such 
as MRIs of the head after mild trauma that are unnecessary according to 
professional guidelines but are done just in case of a lawsuit.”161 
This connection between exorbitant health care costs and the fear of 
being sued is easily understood. Aside from being expensive for physicians, 
the medical-malpractice system cripples the patient. There are three general 
goals, or purposes, that the medical-malpractice system aims to accomplish: 
first, to make sure that patients who are injured by a physician’s negligence 
are adequately compensated in a reasonable time frame; second, to ensure 
                                                     
156 Id. 
157 Dixon Davis, Malpractice Insurance: What Physicians Need to Know, PHYSICIANS 
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accountability among physicians, hospitals, and other health care providers; 
and third, to improve the quality of health care by deterring negligent 
behavior from physicians and other health care providers.162 
The inefficiency problem of the medical-malpractice system is 
harmful to fertility plaintiffs around the country. Harvard researchers 
conducted a study that looked into just how inefficient medical malpractice 
truly is. The study involved more than 30,000 medical records in the state of 
New York and came to the conclusion that “97% of the time when a physician 
or hospital commits a mistake that harms a patient, there is no lawsuit.”163 
Dr. Emanuel explained: 
The malpractice system is . . . not efficient. . . . [T]he average 
time to settle a malpractice lawsuit is 20.3 months. Further, 
only about 40 cents of every dollar in malpractice premiums 
paid by physicians goes to injured patients; the rest is absorbed 
in administrative and litigation costs and insurance company 
profits.164 
The inefficiency of the medical-malpractice system in the United 
States is harmful to both physicians and patients alike. The three general 
goals of the medical-malpractice system (timely compensation, 
accountability, and deterrence) are not being met; therefore, there is a need 
for medical-malpractice reform in the United States. Until this reform can 
take place, three-parent IVF will need something to ensure remedies for 
injured fertility patients.  
IV. TOWARD A SOLUTION: THREE-PARENT IVF AND MEDICAL 
MALPRACTICE IN THE UNITED STATES 
The law is usually slow when dealing with new developments in 
technology.165 There are currently no legal theories or claims that are 
available specifically for IVF plaintiffs: therefore, no claims will exist for 
three-parent IVF plaintiffs, either.166 Legal practitioners often use existing 
legal theories, such as tort law and contract law theory, to deal with new 
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technological developments.167 For example, an IVF plaintiff will oftentimes 
claim breach of contract when seeking damages.168 Legislation is currently 
silent on the specific legal remedies that are available to IVF plaintiffs, hence 
the need for the application of other legal theories. The immediate need is for 
specific legislation addressing IVF liability in the United States; in the future, 
three-parent IVF liability must also be addressed. Regular IVF and three-
parent IVF liability should be treated differently, as three-parent IVF 
procedures are riskier and more complex. The science behind three-parent 
IVF is also in its infancy, unlike regular IVF, so considerable precautions 
should be taken as the law moves forward to deal with what liability to assess. 
This section will recommend legislation addressing three-parent IVF liability 
in regards to the following: (1) the standard of care given by physicians; (2) 
the informed consent standard imposed on physicians; and (3) the medical-
malpractice arena concerning three-parent IVF procedures—specifically the 
implementation of a fertility court. 
A. Recommendations for Three-Parent IVF in the United States 
1. Implement three-parent IVF as a clinical trial to conduct 
research. Three-parent IVF is in its infancy, and much research is needed to 
ensure that it is reasonably safe. The lack of empirical evidence to show that 
three-parent IVF is safe is a primary reason for countries holding back from 
legalizing the procedure.169 Another reason is the argument that three-parent 
IVF could lead to “designer babies.”170 To date, the United Kingdom is the 
only country that has legalized the procedure.171  Other countries, such as 
Mexico and Ukraine, are silent on the procedure, which is likely part of the 
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reason that fertility physicians have performed procedures in those countries. 
Legislation in the United States is unlikely to occur in the near future, at least 
until more rigorous testing and research can be conducted on three-parent 
IVF’s safety and effectiveness. 
However, this should not prevent women who suffer from mitochon-
drial disease from having healthy children in the United States. If they so 
choose, the option should be available to them within the borders of the 
United States before legislation fully legalizes the procedure. This Comment 
recommends that three-parent IVF be implemented in the United States as a 
clinical trial172 to procure the necessary data required to make an educated 
decision on proper legislation going forward. Those who choose to have a 
child using the three-parent IVF procedure in the United States shall 
participate (as a patient in the clinical trial) in a follow-up program, primarily 
for purposes of monitoring the child into adulthood. This will allow scientists 
and researchers to assess and monitor risks and outcomes, with the long-term 
goal of gathering enough empirical evidence to write legislation to formally 
legalize three-parent IVF in the United States as a fertility treatment. 
2. The need for an evidence-based standard of care for three-
parent IVF procedures in the United States. Three-parent IVF is new, 
innovative, and groundbreaking in fertility medicine. A medical standard of 
care needs to be able to keep up with the implementation of such a procedure, 
and the customary care standard is not sufficient to adequately serve the 
purposes of three-parent IVF. The customary care model of medical practice 
is based on physician preferences that are grounded in tradition, opinion, or 
clinical experience and not on objective, scientific evidence.173 It is quite 
evident that this standard will fall short, because there will be no clinical 
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experience or tradition of three-parent IVF from which physicians can glean 
a standard. Three-parent IVF desperately needs an evidence-based standard 
to be implemented because it will ensure that objective, scientific evidence 
will be properly considered in the decision-making process by physicians 
when treating patients. Evidence-based medicine relies heavily on scientific 
data to allow physicians to make informed decisions regarding patient care. 
Skeptics will argue that this will create a problem in courts dealing with three-
parent IVF cases, since scientific data will be sparse in the beginning stages 
of clinical trials.174 Although it is true that three-parent IVF has limited 
scientific evidence of its effectiveness and safety to date, this hurdle will be 
overcome by looking to other countries around the world, including the 
United Kingdom, to see clinical outcomes and safety. 
3. Informed consent standards for three-parent IVF: the 
reasonable patient standard over paternalism. Patients are increasingly 
becoming more involved with their own care.175 “[H]ealth care leaders are 
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focused more than ever on patient engagement as a key to driving down costs 
and improving outcomes.”176 Fertility treatment, in particular, is a sensitive 
topic to discuss, and a woman who consents to a procedure as intimate as 
three-parent IVF must be afforded the right to be involved in her care every 
step of the way. The only standard that can adequately meet this burden is the 
reasonable patient standard. In order for this standard to be fully effective, 
the healthcare system must define a specific role for the patient within the 
delivery of care.177 In essence, we need to define the role of the patient as a 
person with a job:178  
If the patient is to have a job in the care-delivery process, we 
must apply the same principles of intentional work design to 
their jobs as we do to those of physicians and clinical staff. . . 
. 
We know from classic management theory . . . applied and 
tested in other service-industry contexts what good job design 
looks like. Well-designed jobs, for example, give individuals 
a clearly defined role to play with sufficient autonomy and 
regular performance feedback built in. This not only allows 
people to execute tasks effectively but also gives them a sense 
of meaning and satisfaction in their work by seeing the 
connection between their efforts and outcomes.179 
It is important that patients are given the opportunity to play a meaningful 
role in the administration of three-parent IVF because, like most ART 
procedures, it will likely include very personal and patient-specific needs. 
Medical professionals are some of the most skilled and valuable 
people in society. But just as with any other profession, they are not without 
fault. As discussed earlier, physicians make mistakes and these mistakes can 
oftentimes lead to injuries—both physical and psychological—to their 
patients. The manner in which these injuries are remedied must be equitable 
for each and every patient, because injured patients should not be required to 
live with an injury without just compensation. Since filing a medical-
malpractice lawsuit can be costly, to the point of being out of reach for some 
patients due to cost, there needs to be an alternative way to reach equitable 
solutions for all fertility plaintiffs. This Comment proposes the establishment 
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of a fertility court within the United States Court of Federal Claims to provide 
a no-fault system for injured fertility plaintiffs who are seeking compensation 
for their injuries. 
B. A Lesson Learned from Vaccines: A Need for Fertility Court 
 It is no secret that filing a medical-malpractice lawsuit can be 
expensive. So many would-be plaintiffs choose not to file suit due to the 
inherent risks that run with filing such a lawsuit. These are people who have 
suffered real and cognizable injuries—yet they choose to forgo compensation 
due to the costly nature and uncertainty of a medical-malpractice lawsuit. 
This generally limits injury awards in medical-malpractice cases to the upper-
class plaintiffs who have the money to file these suits. In the 1980s, 
pharmaceutical companies were being hit hard with lawsuits over select 
childhood vaccines.180 These lawsuits created uncertainty regarding vaccine 
shortages, with the fear that preventable diseases would make a resurgence if 
vaccine companies stopped manufacturing vaccines.181 In 1986, the 
implementation of the National Vaccine Injury Compensation Program 
(NVICP)182 attempted to remedy this dilemma by providing financial 
compensation to plaintiffs who filed a petition with the United States Court 
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of Federal Claims,183 and were found to have been injured by a NVICP-
covered vaccine.184 The NVICP provides a no-fault resolution for vaccine 
injury petitions.185 “Congress intended that the Vaccine Program provide 
individuals a swift, flexible, and less adversarial alternative to the often costly 
and lengthy civil arena of traditional tort litigation.”186 The vaccine court fund 
was created by the administration of a 75-cent tax for every dose of a vaccine 
sold by the pharmaceutical companies.187 Vaccine courts have encouraged 
pharmaceutical companies to continue developing much needed vaccines by 
largely decreasing their litigation liability. It also provides a remedy for 
injured plaintiffs, who may not have the necessary funds to file a lawsuit, to 
seek compensation for their injuries caused by vaccines. 
 This Comment proposes the implementation of a fertility court within 
the United States Federal Court of Claims to combat the same inequities that 
the vaccine court dealt and still deals with on a regular basis. Like vaccine 
court, it will operate as a no-fault court. Three-parent IVF requires such a 
court, along with other ART procedures, to ensure that fertility plaintiffs are 
justly compensated for their injuries and to reduce the occurrence of fertility 
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malpractice litigation. An injured three-parent IVF patient should not be left 
out in the cold due to her inability to finance a costly medical-malpractice 
lawsuit. A fertility court will ensure that injured three-parent IVF patients 
will always have an available remedy, regardless of financial or 
socioeconomic status. 
1. Funding fertility court: a licensing fee to a federal fertility 
fund. Vaccine court is funded by a taxing system where the pharmaceutical 
companies pay a 75-cent tax for every dose of vaccine they sell. This 
incentivizes the pharmaceutical companies to pass the cost to the consumers 
through an increased vaccination price. It is proposed that Congress enact 
legislation to require a “licensing fee” to be administered to patients by every 
fertility physician who performs fertility treatment. 
Fertility physicians who administer the three-parent IVF procedure in 
the United States would charge their fertility patients a fee that would be 
directly routed to a fertility court fund. The incentive for such a system will 
be a two-way street. First, it incentivizes the physician to charge the fee 
because she will be able to provide three-parent IVF procedures to patients 
without adding cost to her own practice of medicine. Second, it incentivizes 
the patient to pay the fee because she will have the opportunity to have the 
procedure done at home in the United States, and she will have the peace of 
mind that a fertility court will be there to support her if she is injured from 
the procedure. 
Funding fertility court this way will benefit both the physician and the 
patient. As discussed earlier, defensive medicine practices are a prevalent 
problem in the United States. The inefficient practice of defensive medicine 
can largely be attributed to fear that a physician feels about looming medical-
malpractice lawsuits. A fertility court will help remedy defensive medicine 
practices among fertility physicians by lowering their medical-malpractice 
insurance premiums, as medical-malpractice litigation liability for ART 
procedures will likely plummet due to the availability of a fertility court. 
2. A fertility court will lower medical malpractice insurance 
premiums for fertility physicians by reducing their litigation liability. 
Physicians who practice fertility medicine experience some of the most 
outrageously high medical-malpractice premiums in the United States—
some paying as much as $195,000 annually in premium payments alone.188 
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Routing a majority of fertility plaintiffs to a fertility court should drastically 
lower the medical-malpractice premiums for fertility physicians, as the 
litigation liability should lower significantly. Fertility physicians may be 
hesitant to perform a three-parent IVF procedure because it could mean even 
higher medical-malpractice insurance premiums due to the procedure’s 
technical nature and infancy status. This concern is valid and would be 
addressed by the implementation of a fertility court. Fertility physicians will 
likely see their medical-malpractice insurance premiums lower because they 
will have less exposure with the existence of a fertility court. Fertility 
plaintiffs will have the option to file a claim with fertility court instead of 
being required to hire an attorney to sue a medical-malpractice insurance 
carrier, which is costly, time-consuming, and stressful. 
In the 1980s, pharmaceutical companies that manufactured select 
vaccines nearly stopped making them due to overexposure to litigation 
liability. The implementation of a vaccine court significantly dropped that 
liability and allowed pharmaceutical companies to continue manufacturing 
important and life-saving vaccines—all of which would not have been 
possible without a vaccine court. 
The implementation of three-parent IVF in the United States needs to 
be followed by the establishment of a fertility court, following in the 
successful footsteps of the vaccine industry. Implementing three-parent IVF 
without a fertility court would likely have negative consequences. It would 
discourage fertility physicians from performing the procedure altogether, out 
of fear of the possibility of increased medical-malpractice litigation. It would 
also discourage patients from seeking out the procedure due to the inability 
to remedy an injury, if one were to occur. Fertility court provides a solution 
for both of these concerns. 
CONCLUSION 
 Three-parent IVF is here and most likely to stay. The United Kingdom 
has rung in a new era in fertility medicine by legalizing three-parent IVF—
giving women with mitochondrial disease new hope. Legislation in the 
United States to regulate three-parent IVF as a clinical trial is necessary to 
help rid the world of mitochondrial disease. The legislation must stress the 
importance of safety regulations that are already in place for tissue donation 
and transplantation. 
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 Three-parent IVF legislation is also needed to address the cost and 
efficiency problems of the medical-malpractice system in the United States. 
The benefits of implementing a fertility court would be two-fold. First, it 
should drive down medical-malpractice premium payments for fertility 
physicians, as their litigation liability will likely fall. Second, it should give 
all fertility plaintiffs a viable option to be compensated for their injuries. The 
importance and value of having a no-fault court system for three-parent IVF 
and other fertility injuries should increase the efficiency and reduce the cost 
of the medical-malpractice system in the United States. 
 This legislation will ensure that women, from all walks of life, who 
suffer from mitochondrial disease can have the opportunity to rear and raise 
their own genetic children. United States citizens should not be hindered 
when it comes to the right to create a family. Legislation needs to reflect this 
precious and sacred societal value. 
